ERBB2 and breast carcinoma: These datasets included TBCP-1 cells, a mouse HER2-overexpressing breast cancer cell line capable of metastasising to the brain, treated with neratinib for 24 h, and intracranial human EGFR/HER1-mutant TS895 glioblastoma xenograft treated with neratinib for 3 h [14, 31].